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The role of oxytocin in empathy to the pain of
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Background. Oxytocin (OT) is associated with our ability to empathize and has been shown to play a major role in med-
iating social behaviors within the context of intergroup dynamics. Schizophrenia is associated with impaired empathy,
and with a dysfunctional oxytocinergic system. The effect of OT on the empathic responses of patients with schizo-
phrenia within the context of intergroup relationships has not been studied. The present study examined the effect of
OT on the patients’ empathic responses to pain experienced by in-group, conﬂictual out-group and neutral out-group
members.
Method. In a double-blind, placebo-controlled, within-subject cross-over design, the responses on the Pain Evaluation
Task of 28 male patients with schizophrenia were compared to 27 healthy male controls. All participants received a single
intranasal dose of 24 IU OT or placebo, 1 week apart.
Results. OT induced an empathy bias in the healthy controls towards the conﬂictual out-group members. Although this
effect was absent in the patient group, OT seems to heighten an empathic bias in the patient group towards the in-group
members when rating non-painful stimuli.
Conclusions. The study demonstrates that the administration of OT can result in empathic bias towards adversary
out-group members in healthy controls but not in patients with schizophrenia. However, the OT-induced bias in both
the patients (in the no-pain condition towards the in-group members) and the healthy controls (in the no-pain
and pain conditions towards the adversary out-group) suggests that OT enhances the distinction between conﬂictual
in-group and out-group members.
Received 10 October 2013; Revised 21 March 2014; Accepted 27 March 2014; First published online 24 April 2014
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Introduction
Empathy can generally be deﬁned as an affective re-
sponse to another’s individual distress, which requires
an accurate understanding of another’s mental state or
frame of reference (Batson et al. 1987). In addition to its
association with a myriad of sociocognitive dysfunc-
tions, schizophrenia is associated with impaired empa-
thy (Abu-Akel & Abushua’leh, 2004; Bora et al. 2008;
Derntl et al. 2009; Smith et al. 2013). For example,
Bora et al. (2008) reported that, compared to healthy
controls, patients with schizophrenia exhibited severe
empathy dysfunctions as measured by the Empathy
Quotient questionnaire (Baron-Cohen & Wheelwright,
2004). They also found impairments in the ability of
the patients with schizophrenia to recognize and rea-
son about emotions, which are considered core compo-
nents of empathy (Blair, 2005; Shamay-Tsoory, 2011).
Similarly, Derntl et al. (2009) found that patients with
schizophrenia exhibited a generalized deﬁcit in all
core components of empathy, including emotion rec-
ognition, perspective taking and affective responsive-
ness. More recently, Lee et al. (2011) investigated
empathic accuracy (deﬁned as the ability to accurately
infer the affective state of another person) and reported
that patients with schizophrenia not only have lower
empathic accuracy compared to controls but also are
less sensitive to the social cues of others when making
those judgments.
Several studies have suggested that the neuropep-
tide oxytocin (OT) mediates empathy (Rosenfeld et al.
2011; Striepens et al. 2011). This has been demon-
strated in both healthy (Hurlemann et al. 2010) and
pathological populations such as those with autism
(Guastella et al. 2010). Studies have also shown
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abnormal levels of OT in the plasma (Goldman et al.
2008) and cerebrospinal ﬂuid (Linkowski et al. 1984;
Beckmann et al. 1985; Legros et al. 1992) of patients
with schizophrenia and, more recently, variations in
the OT receptor gene have been linked to schizo-
phrenia (Souza et al. 2010; Montag et al. 2012a,b).
Because of these associations, research concerned
with the therapeutic potential of OT in schizophrenia
has intensiﬁed over the past few years (Davis et al.
2013). Findings suggest that endogenous OT levels
are signiﬁcantly associated with social functioning
(Keri et al. 2009; Rubin et al. 2010; Sasayama et al.
2012) and that the administration of OT improves
symptomatology (Bujanow, 1974; Caldwell et al. 2009;
Feifel et al. 2010; Pedersen et al. 2011), social perception
(Fischer-Shofty et al. 2013) and verbal memory (Feifel
et al. 2012). In addition, OT has been shown to improve
emotion recognition (Averbeck et al. 2012) and theory
of mind abilities (Pedersen et al. 2011). These associ-
ations suggest that OT might have a bearing on both
the psychopathology and sociocognitive functioning
of individuals with schizophrenia. Thus, in considering
the general role of OT in social interaction and empathy,
the established abnormalities of individuals with
schizophrenia in sociocognitive and empathic abilities
and the positive normalizing effect of OT on various
aspects of social dysfunction seen in schizophrenia,
it can be hypothesized that the normalizing effect of
OT in schizophrenia can also be extended to empathy.
One of the most rudimentary empathy mechanisms
is that of empathy to pain, a concept that describes our
tendency to automatically experience distress when
facing someone else’s pain. Previous human imaging
studies focusing on empathy for others’ pain have con-
sistently shown activations in regions also involved
in direct pain experience (Jackson & Decety, 2004;
Singer et al. 2004; Decety & Lamm, 2006). Speciﬁcally,
a neural network including the anterior cingulate
cortex and the anterior insula was reported to respond
to both felt and observed pain (Decety et al. 2010). The
same sets of regions have been reliably observed across
a wide range of individuals and circumstances, sug-
gesting that empathy to pain is, at least in part, an
automatic, bottom-up process and perhaps an evolved
adaptation (Decety & Svetlova, 2012). However, re-
search strongly suggests that empathy is also mediated
by top-down processing. Indeed, neuroimaging stud-
ies have demonstrated that the empathic response
to pain is either strengthened or weakened when con-
textual and interpersonal variables are manipulated,
including the intent of the inﬂictor of pain to harm
the target (Akitsuki & Decety, 2009), and whether the
person in pain belongs to a stigmatized group (Tarrant
et al. 2009; Decety et al. 2010). This suggests that empa-
thy to pain is also modulated by top-down processes
such as group membership. Although this ‘in-group
empathy bias’ has been repeatedly reported in healthy
participants (Trawalter et al. 2012), it is not known
whether patients with schizophrenia also exhibit this
bias.
The role of OT and empathy has been extensively
researched in the context of intergroup relationships
in healthy controls, showing that the administration
of OT favorably promotes empathy towards in-group
members (De Dreu et al. 2011). The work of De Dreu
et al. (2010, 2011) has also shown that raising OT levels
can lead to negative reactions towards out-group
members such as out-group derogations and defensive
aggression. To our knowledge, the effect of the admin-
istration of OT on such bias among patients with
schizophrenia has not been investigated. In addition,
we are not aware of any studies that have examined
whether patients with schizophrenia have inherent
social biases towards in-group versus out-group mem-
bers. With respect to studying the effect of OT on
empathy in schizophrenia, we are aware of only one
study (Davis et al. 2013). In this double-blind, placebo-
controlled study, the administration of a single dose of
40 IU intranasal OT did not improve the patients’ em-
pathic responses as measured by the Emotional
Perspective Taking Task (EPTT; Derntl et al. 2009), in
which participants were required to infer the emotional
expression of a masked-face individual taking part in
a two-person social interaction. Of note, however, the
authors reported a positive effect on the composite
score of several higher-level processes, including the de-
tectionof sarcasmanddeception in addition to empathy.
Accordingly, using a double-blind cross-over design,
we sought to examine in a group of individuals with
schizophrenia the effect of intranasal administration
of OT on their empathic responses to the pain of others.
A unique aspect of our study is that we tested the
inﬂuence of OT on the empathic responses of patients
within the context of the Israeli–Palestinian conﬂict in
Israel. This allowed us to examine, in an ecologically
valid environment, the role of this neuropeptide in
modulating the patients’ empathic responses to mem-
bers of a group who are part of a protracted intergroup
violent conﬂict. Accordingly, this study evaluated
whether patients with schizophrenia have a group
bias, often exhibited by healthy participants, towards
in-group versus out-group members, and the extent
to which this bias, or lack thereof, is moderated by
the administration of intranasal OT.
Method
Participants
Twenty-eight healthy men, ranging in age from 20
to 37 years (mean age=27.43 years, S.D.=3.44), and
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28 male patients with schizophrenia, ranging in age
from 22 to 45 years (mean age=32.21 years, S.D.=6.05)
were included in the study. Because of known signiﬁ-
cant hormonal interactions between OT and estrogen
in women (McCarthy, 1995), an all-male sample elim-
inates this possible confound. During the course of
the experiment, one participant from the control
group dropped out, bringing the ﬁnal sample to a
total of 55 participants. The data reported here are
thus for 27 healthy participants and 28 patients with
schizophrenia. All participants were Israeli Jews and
living in Israel at the time of assessment. Healthy par-
ticipants were recruited through advertisement posted
across campus at the University of Haifa, and the
patients were recruited from out-patient and day
clinics. Diagnosis of schizophrenia was based on the
Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID) and conﬁrmed by two psychiatrists.
The individuals with schizophrenia were stabilized on
ﬁxed doses of an equivalent antipsychotic medication
with or without trihexyphenidyl (Artane, 5–0mg/day)
or biperiden (Dekinet, 2–4mg/day). Exclusion criteria
were acute, unstable, signiﬁcant or untreated medical
illnesses (including arrhythmia, psychiatric conditions
and head injury), mental retardation (IQ<75), and dis-
turbances in visuomotor coordination. The study was
approved by the National Institutional Review Board
of Israel and all participants gave their signed informed
consent.
Clinical assessment
The patients with schizophrenia were assessed by
a clinical psychologist with validated clinical tests
suitable for evaluating their condition and the severity
of speciﬁc symptoms. The Positive and Negative
Syndrome Scale (PANSS; Kay et al. 1987) was used to
evaluate the presence/absence and severity of positive,
negative and general psychopathology. This was
assessed during the screening session. The Clinical
Global Impression (CGI) scale was used to estimate
the severity of each patient’s illness. This was adminis-
tered during the ﬁrst and second sessions of the treat-
ment protocol. Finally, the Shipley Institute of Living
Scale (SILS; Shipley, 1940) was used to assess the intel-
lectual abilities of the participants.
After giving their oral and written informed consent,
the participants were instructed to avoid using psycho-
tropic substances (e.g. caffeine and nicotine) for at least
12 h prior to the experiment.
Treatment administration
A double-blind, within-subject, cross-over design was
used, with participants randomly assigned to groups
for the ﬁrst administration of either OT or placebo
45min prior to performing the behavioral task. Those
initially receiving OT were administered a single intra-
nasal dose of 24 IU (Syntocinon-Spray, Novartis,
Switzerland) by three puffs in each nostril (each puff
contains 4 IU). The placebo contained all inactive in-
gredients without the neuropeptide. Seven days later,
at the second session of the experiment, participants
underwent the same procedure with the other sub-
stance (i.e. placebo or OT). Previous studies show
that the elevation of OT following intranasal adminis-
tration (24 IU) usually lasts for only 1–2 h (Born et al.
2002; Gossen et al. 2012). Hence, it was safe to assume
that there was no carry-over effect between the two
sessions.
Assessment of empathy to pain: the Pain
Evaluation Task
In this study, we used the Pain Evaluation Task
designed by Jackson et al. (2005). We chose this task be-
cause previous research using this task and similar
empathy-for-pain paradigms has shown that it reliably
induces an empathy bias towards in-group compared
to out-group members (Hein et al. 2010; Shamay-
Tsoory et al. 2013). The task consists of showing a series
of digital color photographs depicting right hands
and right feet in painful and non-painful situations
as follows: (1) right hands in painful situations, (2)
right hands in neutral situations, (3) right feet in pain-
ful situations, and (4) right feet in neutral situations.
All situations depict familiar events that can occur in
everyday life. Various types of pain (mechanical, ther-
mal and pressure) are represented. For each painful
situation there is a corresponding neutral picture that
involved the same setting without any painful com-
ponent. Stimuli were presented randomly, following
a 750-ms presentation of different common names of
Jews (representing the in-group members), Palestinian
Arabs (representing the adversary out-group mem-
bers) or Europeans (representing the neutral out-group
members). Following each name, a picture showing
either a painful or a non-painful situation was pre-
sented (see Fig. 1). Participants were then asked to
rate, as quickly as possible, the intensity of the pain ex-
perienced by the target using a visual analog scale
(VAS) using the computer mouse (from 0=no pain to
10=most painful). The experiment consisted of 30 trials
in total (15 painful and 15 non-painful stimuli). The
same name was always tagged with the same picture
in all sessions, but the order of presentation of the
pain and no-pain stimuli were randomized separately
for each participant. The task began with three practice
trials, followed by the test blocks. The task was admin-
istered using E-prime 2.1 (Psychology Software Tools
Inc., USA).
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Selection of the protagonist names
The selection of the targets’ names was based on a
preliminary study in which 120 students from the
University of Haifa (60 Palestinian Arabs and 60
Jews), all Israeli citizens, were asked to report what
they believe are the ﬁve most common names of
Palestinian Arabs, Jews and Europeans. From a total
list of 96 names, ﬁve names with the highest frequency
were selected for each group. Because, in the current
study, all the participants were Israeli Jews, we only
used the prototypical names reported by the Jewish
students. Accordingly, the stereotypical Jewish names
were Moshe, Avi, Yits’hak, Yesrael and Shimon. The
Arab names were Ahmad, Mohammed, Abed, Saleem
and Ali. The European (neutral out-group) names
were Chris, John, Mark, Martin and Paul. The use of
names to prime group membership is motivated by
studies showing that the presentation of prototypical
names is sufﬁcient to prime afﬁliative biases of
in-group and out-group membership (De Dreu et al.
2011; Bruneau et al. 2012; Shamay-Tsoory et al. 2013).
Statistical approach and analysis
The double-blind, placebo-controlled design adopted
in the current study enabled us to assess within and
across groups the effect of OT versus placebo on the
empathy rating of perceived pain when viewing
in-group, adversary or neutral out-group members
(primed by their respective prototypical names) in
painful and non-painful familiar situations. The cur-
rent study thus used a 2×3×2×2 design, where treat-
ment (placebo versus OT), target (Jew versus
Palestinian Arab versus European) and stimuli (painful
versus non-painful) were entered as within-subject fac-
tors and patients versus healthy controls as between-
subjects factors. In addition, independent-sample t
tests and correlation analyses were carried out. All
analyses were performed using IBM SPSS version 21
(SPSS Inc., USA).
Results
Independent-sample t tests indicated that the control
and patient groups differed in age (t53=−3.54, p=
0.001) but not intelligence (t53=1.74, p=0.09). None of
the empathy responses of both groups correlated
with either the intelligence score or age. In addition,
none of the empathy responses within the schizo-
phrenia group correlated with age of disease onset,
duration of illness, positive or negative symptoms, or
general psychopathology. There were also no associa-
tions between the patients’ responses and severity of
illness as measured by the CGI scale during the ﬁrst
or the second session. Moreover, there was no differ-
ence in the patients’ severity of illness during the ﬁrst
versus the second session. The clinical and demo-
graphic data for the patient and healthy control groups
are presented in Table 1.
Effect of OT on empathy to pain
The full model of the study design included three
within-subject variables (target, pain condition and
treatment) and one between-subjects variable (group).
To examine the interaction between treatment (pla-
cebo/OT), target (Arab/European/Jew), pain condition
(pain/no-pain) and group (control/schizophrenia), a
four-way (2×3×2×2) repeated-measures ANOVA was
performed. The results show a non-signiﬁcant treat-
ment effect (F1,53=1.02, p=0.32), a non-signiﬁcant tar-
get effect (F2,106 =0.75, p=0.47) and a non-signiﬁcant
group effect (F1,53=0.45, p=0.51). The pain condition
effect was highly signiﬁcant (F1,53 =48.50, p<0.001,
ηp
2 =0.90), indicating that overall the ratings for the
Fig. 1. Sample presentation of a right hand in a pain and no-pain situation.
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painful stimuli were higher than the non-painful
stimuli. Furthermore, the two-way interactions of
group× treatment (F1,53 =2.52, p=0.12) and target×
group (F2,106=2.75, p=0.07) were also not signiﬁcant.
Importantly, the three-way interaction of treatment×
target×group (F2,106=4.05, p=0.020, ηp
2 =0.07) was sign-
iﬁcant, indicating that the treatment affected the
groups differently when judging the stimuli associated
with the different targets. The within-subjects contrast
for this interaction is linearly signiﬁcant (F1,53 =8.17,
p=0.006, ηp
2 =0.13), suggesting that the participants’
ratings across the three targets followed a linear
trend. The four-way interaction of treatment× target×
condition×group was not signiﬁcant (F2,106=0.260,
p=0.772).
To further explore the source of the three-way inter-
action, we carried out separate repeated-measures
ANOVAs for each group. Using a three-way repeated-
measures ANOVA, we examined the interaction between
treatment (placebo/OT), target (Arab/European/Jew)
and pain condition (pain/no-pain) within the healthy
controls. As shown in Fig. 2, a signiﬁcant treatment
by target effect (F2,53 =6.74, p=0.002, ηp
2 =0.21) indicated
that, in the healthy controls, the treatment differen-
tially affected the pain ratings of the different target
groups. Although the pain condition was highly sign-
iﬁcant (F1,26=183.95, p<0.001, ηp
2 =0.88), indicating
higher pain ratings in the pain versus no-pain con-
dition, the three-way interaction of treatment× target×
pain condition was not signiﬁcant (F2,52=0.66, p=0.52).
The target (F2,52=0.434, p=0.65) and treatment (F2,52 =
2.62, p=0.12) effects were also not signiﬁcant. To
further explore the source of the two-way treatment
by target interaction, follow-up t tests were carried
out. This analysis indicated that OT had a signiﬁcant
effect on increasing the pain rating for the Arab prota-
gonists (t26=2.06, p=0.049) but it did not affect the pain
rating for the European (t26 =−0.59, p=0.56) or Jewish
targets (t26=−0.56, p=0.58). Of note, similarly to the
pain ratings, in the no-pain condition, OT had a sign-
iﬁcant effect on increasing the empathy to pain ratings
for the Arab targets (t26=3.27, p=0.003) and for the
European targets (t26=2.31, p=0.029) but non-
signiﬁcantly for the Jewish targets (t26=1.37, p=0.18).
Within the patient group, we similarly examined the
interaction between treatment (placebo/OT), target
(Arab/European/Jew) and pain condition (pain/
no-pain) using a three-way repeated-measures
ANOVA. As shown in Fig. 3, a non-signiﬁcant treat-
ment by target effect (F2,54=0.82, p=0.45) indicated
that, in the patient group, the treatment did not differ-
entially affect their empathy to the pain of the different
targets. Although the pain condition was highly sign-
iﬁcant (F1,27 =318.07, p<0.001, ηp
2 =0.92), indicating
higher pain ratings in the pain versus no-pain con-
dition, the three-way interaction of treatment× target×
pain condition was not signiﬁcant (F2,54=0.12, p=0.89).
The target (F2,54 =2.70, p=0.11) and treatment (F2,54=
0.23, p=0.64) effects were also not signiﬁcant.
When examining the within-subject contrasts
reported above, no signiﬁcant differences were dis-
cerned across the targets in the placebo condition for
both the painful and non-painful stimuli. However,
under the OT condition, the patients, but not the con-
trols, rated the non-painful stimuli differently across
the targets. Paired t tests reveal that the Jewish targets
received signiﬁcantly higher ratings than both the
Arab targets (t27=3.17, p=0.004) and the European
targets (t27=2.38, p=0.024). The European targets also
received higher rating than the Arab targets, but
the difference did not reach signiﬁcance (t27=1.34,
p=0.19).
Discussion
The current study sought to investigate the effect of
OT on the empathic responses of male patients with
schizophrenia and male healthy controls within the
context of intergroup relationships. The healthy and
the patient groups behaved differently in their em-
pathic responses towards the conﬂictual group mem-
bers as a function of OT administration. Within the
controls, OT induced a signiﬁcant empathy bias
towards the Arab targets in the painful condition. A
similar but a more robust bias towards the Arab targets
was also observed under the OT condition when rating
non-painful stimuli. Within the schizophrenia group,
Table 1. Clinical and demographic data of the patient and healthy
control groups
Schizophrenia sample
(n=28 males)
Healthy controls
(n=27 males)
Age (years) 32.21±6.05 27.48±3.49
Intelligence
(SILS)
25.21±8.39 29.64±6.20
Age of onset
(years)
20.21±4.20 –
Duration of
illness (years)
11.93±6.54 –
PANSS Negative 18.68±4.70 –
PANSS Positive 15.14±3.73 –
PANSS General 33.79±6.03 –
CGI Session 1 4.71±0.66 –
CGI Session 2 4.61±0.83 –
SILS, Shipley Institute of Living Scale; PANSS, Positive
and Negative Syndrome Scale; CGI, Clinical Global
Impression.
Values given as mean±standard deviation.
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the empathy ratings of the targets did not differ as
a function of treatment condition when evaluating
others in pain. However, OT seems to heighten the
bias within the patients when rating non-painful stim-
uli. Under this condition, the patients signiﬁcantly
conferred higher empathy ratings to the Jewish targets
(i.e. the in-group members), followed by the European
targets and then the Arab targets. Thus it seems that
OT exerts opposing effects on the rating of non-pain-
ful stimuli within the healthy and patient groups;
although OT increased the level of empathy in the
healthy participants towards out-group members, it
increased the bias among the patients towards the
in-group members.
From a clinical perspective, OT did not increase the
patients’ empathic responses in the painful condition.
This ﬁnding partially overlaps with the study by
Davis et al. (2013), who reported that OT did not
improve the empathic responses of their patients as
measured by the EPTT. However, as noted earlier,
0
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Placebo No-Pain Oxytocin No-Pain Placebo Pain Oxytocin Pain
Arab Euro Jew
Fig. 2. Mean empathic ratings (± standard error) of the healthy controls as a function of treatment condition (placebo versus
oxytocin), pain condition (pain versus no-pain) and target (Arabs versus Europeans versus Jews). VAS, Visual analog scale.
0
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S
Placebo No-Pain Oxytocin No-Pain Placebo Pain Oxytocin Pain
Arab Euro Jew
Fig. 3. Mean empathic ratings (± standard error) of the patients with schizophrenia as a function of treatment condition
(placebo versus oxytocin), pain condition (pain versus no-pain) and target (Arabs versus Europeans versus Jews). VAS, Visual
analog scale.
3528 A. Abu-Akel et al.
that study found a positive effect on a composite score
of several higher-level cognitive processes, including
empathy. The absence of the effect of OT among the
patients can be attributed to variations within the
patients’ neurochemical proﬁle with which OT inter-
acts, including variation in endogenous OT and the
possible modulatory effect it may have on exogenous
OT (Bartz et al. 2011). As such, the lack of a baseline
measure of endogenous OT levels is a limitation in
our study that should be addressed in future studies.
Another possibility is that the administration of one
dose of OT may not be sufﬁcient to induce an effect
on complex sociocognitive abilities, such as empathy,
in the patient group. It is conceivable that a higher
dosage and/or a protracted regimen of daily intranasal
OT administration may be necessary for such an effect
to transpire (Feifel et al. 2010; Pedersen et al. 2011).
A surpising ﬁnding is that OT increased empathic
responses towards the non-painful stimuli, albeit in
opposite trends, in both the patient and healthy parti-
cipants. Although the opposing effect in terms of the
in-group bias (in the patient group) versus the out-
group bias (in the heathy controls) is open to specu-
lation, our ﬁndings suggest that increasing OT levels
facilitate social categorization of others as in-group
versus out-group (Kavaliers & Choleris, 2011; De
Dreu, 2012). Moreover, the enhanced empathic re-
sponse towards non-painful stimuli after the adminis-
tration of OT might be a consequence of an overdrive
of endogenous OT leading to hyper-vigilance/
sensitivity. This may in turn have led participants to at-
tribute social meaning to visual information with when
none is required. This is akin to inducing some form
of hyper-mentalism, which is a common feature in
schizophrenia present with positive symptoms (Abu-
Akel & Bailey, 2000; Frith, 2004; Abu-Akel, 2008;
Montag et al. 2011; Walss-Bass et al. 2013). Another ex-
planation is that both pain and non-pain stimuli rely
on similar neural substrates including the thalamus,
insula and anterior cingulate cortex (Mouraux et al.
2011; Hayes & Northoff, 2012), whose activity cor-
relates signiﬁcantly with the perceived saliency of
the stimulus (Mouraux et al. 2011). Speculatively, the
modulation of the oxytocinergic system of the regional,
along with the connectivity between these different
regions (Bethlehem et al. 2013), may explain the in-
creased ratings we observe for both the painful and
non-painful stimuli.
Within the healthy controls, there was an increase in
the pain ratings to both painful and non-painful stim-
uli in the OT condition, which suggests that OT may
have a general effect on pain perception. This ﬁnding
is commensurate with evidence suggesting that OT
potently affects the nociceptive system when adminis-
tered directly (Juif & Poisbeau, 2013). Moreover, our
study can inform research using intergroup conﬂict
paradigms, particularly in light of the ﬁnding that
OT did not lead the healthy participants to change
their overall ratings towards their in-group members.
Indeed, our ﬁnding suggests that OT can induce an
empathic response towards out-group members even
if the out-group members are part of a social group
with which the participants are engaged in a protrac-
ted political and violent conﬂict. As such, our ﬁnding
does not support claims suggesting that OT promotes,
in healthy controls, out-group derogation or enhances
in-group bias (De Dreu et al. 2010, 2011), and replicates
our earlier results in this regard (Shamay-Tsoory et al.
2013). This ﬁnding might be explained within the
framework of prosocial theories positing that trust
and concern for others tend to increase towards others
in anticipation of future interaction (Komorita & Parks,
1995). It is conceivable that the administration of OT
increases the salience of this likely interaction, which
could explain why the effect was only observed
when rating the Palestinian Arabs (with whom there
is a greater likelihood of interaction) and not the
Europeans. Other possible interpretations pertain to
the role of OT in increasing approach-related behaviors
(Kemp & Guastella, 2011), abolishing negative affect
(Petrovic et al. 2008) and increasing attention to socially
relevant information (Leknes et al. 2013), which
together constitute mechanisms that could facilitate
increased empathic responses towards others. The sel-
ectivity of OT to increasing the empathic response
towards the out-group rather than the in-group sug-
gests that, in certain contexts, exogenous OT may not
necessarily have an additive value to what is already
salient to the individual (i.e. the in-group member).
In this regard there is evidence showing that the ad-
ministration of OT to individuals with high emotional
sensitivity afforded little or no improvement in detect-
ing subtle social cues (Leknes et al. 2013). Thus, our
ﬁnding provides further support for the view suggest-
ing that the effect of OT on sociocognitive abilities is
not uniform and is susceptible to changes in context,
whether it is the environment or the persons with
whom we interact (Bartz et al. 2011).
To conclude, this study demonstrates that the ad-
ministration of OT induces an empathic bias towards
the adversary out-group members in healthy male con-
trols but not in male individuals with schizophrenia.
This suggests that OT, within the context of intergroup
conﬂict, does not affect the patients’ empathic judg-
ments of either neutral or adversary out-group mem-
bers. In this context we should note that the reliance
on an all-male sample may limit the generalizability
of our ﬁndings, particularly in light of evidence sug-
gesting that male and female individuals with schizo-
phrenia differ in baseline OT levels and OT response
Oxytocin and empathy to pain in schizophrenia 3529
(Rubin et al. 2010), and also in their affective mentaliz-
ing abilities (Abu-Akel & Bo, 2013). However, OT does
seem to enhance the distinction between the conﬂictual
in-group and out-group in both the healthy and patient
groups. This is evidenced by the OT-induced bias in
both the patient (in the no-pain condition towards
the in-group members) and the healthy control groups
(in both the pain and no-pain conditions towards the
adversary out-group members), and the absence of
such an effect towards the neutral European group.
This ﬁnding thus underscores the importance of
using both neutral and conﬂict groups in future studies
concerned with intergroup dynamics (see also Bruneau
et al. 2012). The effect of OT on enhancing the salience
and/or social relevance of non-painful stimuli is in-
triguing and warrants further investigation, particu-
larly within the framework of the ‘aberrant salience’
hypothesis of schizophrenia (Kapur, 2003).
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